Including results for coherus investor relations
Search only for chrs investor relations
The Investor Relations website contains information about Coherus BioSciences, Inc.'s business for stockholders, potential investors, and financial ...
Press releases for Coherus BioSciences, Inc., a commercial-stage biopharmacetucial company developing a pipeline of novel immuno-oncology therapies.
The Investor Relations website contains information about Coherus BioSciences, Inc.'s business for stockholders, potential investors, and financial ...
Missing: chrs | Show results with:chrs
People also ask
What happened to Surface Oncology stock?
Who bought surface oncology?
Who are the shareholders of Coherus?
What is the Coherus strategy?
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
Mar 16, 2024 · Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript March 13, 2024 ... Investor Relations for Coherus. ... Stock-Split Stock.
(Coherus, Nasdaq: CHRS), today reported financial ... VP, Investor Relations. IR@coherus.com. . For Media ... Coherus believes that the presentation of these non- ...
Nov 3, 2023 · UBS Biopharma Conference in Miami on Thursday, November 9, 2023, a fireside chat presentation at 11:30 a.m. Eastern Time will be webcast. 6th ...
Find annual and quearterly earnings data for Coherus BioSciences, Inc. Common Stock (CHRS) including earnings per share, earnings forecasts at Nasdaq.com.
REDWOOD CITY, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two ...
(Coherus, Nasdaq: CHRS) today announced the closing of the previously announced ... Marek Ciszewski, SVP Investor Relations. IR@coherus.com. . Media Relations:.